As­traZeneca touts Imfinzi im­munother­a­py com­bos for lung can­cer in push to dri­ve PD-L1 drug up­take

Fac­ing the big dogs in the PD-(L)1 space, As­traZeneca has tak­en its own con­tender Imfinzi in­to block­buster ter­ri­to­ry in its four years on the mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.